Latest localized prostate cancer Stories
Profound Medical announces initiation of U.S.
Profound Medical is pleased to announce that the FDA has granted it IDE approval to conduct a clinical study of its device for the treatment of localized prostate cancer. Toronto,
LYON, France, May 17, 2011 /PRNewswire/ -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with AblathermÂ® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer.
CORAL SPRINGS, Fla., April 12, 2011 /PRNewswire/ -- A prominent prostate cancer specialist is urging men recently diagnosed with localized prostate cancer to carefully review all methods of treatment--treatments that sometimes can result in numerous post-operative quality of life issues including incontinence and impotence, often requiring second surgeries. Dr.
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer.
A comparison of outcomes of different eras of conservative treatment for localized prostate cancer indicates that overall and prostate cancer-specific survival rates are higher for men diagnosed from 1992 through 2002 compared to men diagnosed in the 1970s and 1980s, according to a study in the September 16 issue of JAMA.
SUNNYVALE, Calif., Sept. 9 /PRNewswire/ -- Prostate cancer remains one of the most commonly diagnosed cancers in the United States.
The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.
- A handkerchief.
- Specifically— The legendary sweat-cloth; the handkerchief of St. Veronica, according to tradition miraculously impressed with the mask of Christ; also, the napkin about Christ's head (Johu xx. 7).
- In general, any miraculous portrait of Christ.